PrecisionLife and Ovation to Launch GLP-1 DNA Test by 2026

PrecisionLife and Ovation.io have entered into a collaboration to develop laboratory and consumer genetic tests focused on GLP-1 drug response, announced in a press release. The companies aim to launch a consumer DNA test in the second half of 2026 to help individuals understand their likely safety, efficacy, and tolerability profiles for GLP-1 receptor agonist therapies.

The collaboration builds on PrecisionLife’s analysis of Ovation’s GLP-1 dataset, which identified distinct biomarkers for glycemic control and weight loss. These findings will be validated across additional datasets over the next six months, including studies on semaglutide and tirzepatide. The partners plan to use these insights to support clinical trials and inform reimbursement decisions for payors.

The companies also intend to co-develop laboratory developed tests (LDTs) for use in clinical trials to identify strong responders in new therapeutic areas. Discussions with pharmaceutical partners are underway to integrate these stratification tools into drug development and post-marketing studies.